Efineptakin alfa - Genexine
Alternative Names: Efineptakin alfa NT-I7; GX I7; HyLeukin; HyLeukin-7™; IL-7 Hybrid Fc; IL-7-hyFc; Interleukin-7-hybrid-Fc-recombinant-protein; NT I7; Recombinant human IL-7-hyFc; Recombinant human interleukin-7 hybrid Fc; rhIL-7 - Genexine/I-MAB Biopharma; rhIL-7-hyFc; TJ 107Latest Information Update: 28 Jun 2024
At a glance
- Originator Genexine
- Developer Bristol-Myers Squibb; Fred Hutchinson Cancer Research Center; Genexine; I-MAB Biopharma; Merck & Co; National Cancer Institute (USA); National Institute of Neurological Disorders and Stroke; NeoImmuneTech; PT Kalbe Genexine Biologics; Roche; Yonsei University
- Class Antineoplastics; Antivirals; Immunoglobulin Fc fragments; Immunotherapies; Interleukins; Radioprotectives; Recombinant fusion proteins; Recombinant proteins
- Mechanism of Action Interleukin 7 replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Adenocarcinoma; COVID 2019 infections; Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Squamous cell cancer; Triple negative breast cancer
- Phase I/II Pancreatic cancer; Skin cancer; Small cell lung cancer; Solid tumours
- Phase I Anal cancer; Biliary cancer; Cervical cancer; Diffuse large B cell lymphoma; Kaposi's sarcoma; Ovarian cancer
- Preclinical Acute radiation syndrome
- No development reported Bladder cancer; Breast cancer; Cervical intraepithelial neoplasia; Colorectal cancer; Human papillomavirus infections; Idiopathic CD4-positive T-lymphocytopenia; Lymphoma; Progressive multifocal leukoencephalopathy
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for phase-I development in Progressive multifocal leukoencephalopathy in USA (IM, Injection)
- 04 Jun 2024 Efineptakin alfa - Genexine receives Orphan Drug status for Acute radiation syndrome in Europe
- 04 Jun 2024 NeoImmuneTech plans a clinical trial for Hematologic malignancies, Solid tumours and Autoimmune disorders